Results 341 to 350 of about 564,426 (377)
Hodgkin Lymphoma and Non-Hodgkin Lymphoma [PDF]
Blood and Marrow Transplant Handbook, 2021 Hematopoietic cell transplantation (HCT) is a key treatment modality in the management of advanced Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). Autologous HCT (autoHCT) can be curative for relapsed or refractory HL and diffuse large B-cell lymphoma.
A. Chen
openaire +2 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management
American journal of hematology/oncology, 2022Hodgkin lymphoma (HL) is an uncommon B‐cell lymphoid malignancy affecting 8540 new patients annually and representing approximately 10% of all lymphomas in the United States.
S. Ansell
semanticscholar +1 more source
Concise Notes in Oncology for MRCP and MRCS, 2018
This chapter will discuss the epidemiology, workup, and management of Hodgkin’s lymphoma, with an emphasis on external beam radiotherapy technique and published evidence.
Jason Chan, Steve Braunstein
openaire +3 more sources
This chapter will discuss the epidemiology, workup, and management of Hodgkin’s lymphoma, with an emphasis on external beam radiotherapy technique and published evidence.
Jason Chan, Steve Braunstein
openaire +3 more sources
Medicine, 2013
Hodgkin lymphoma (HL) is a curable malignancy which shows a bimodal curve in incidence in economically developed countries; there is a putative association with Epstein-Barr virus. The WHO 2008 classification schema recognises two histological types of HL: the nodular lymphocyte predominant and the "classic" HL.
Paul Fields, David Wrench
+6 more sources
Hodgkin lymphoma (HL) is a curable malignancy which shows a bimodal curve in incidence in economically developed countries; there is a putative association with Epstein-Barr virus. The WHO 2008 classification schema recognises two histological types of HL: the nodular lymphocyte predominant and the "classic" HL.
Paul Fields, David Wrench
+6 more sources
The Lancet, 2003
Hodgkin's lymphoma was first described in 1832, but the nature of the pathognomic Reed-Sternberg cell, on which diagnosis of the disease is based, has only been elucidated in the past few years. Radiotherapy has been used to treat localised disease since the 1940s, and in the 1960s, effective combination chemotherapy regimens were introduced for ...
Lynny Yung, David C. Linch
openaire +4 more sources
Hodgkin's lymphoma was first described in 1832, but the nature of the pathognomic Reed-Sternberg cell, on which diagnosis of the disease is based, has only been elucidated in the past few years. Radiotherapy has been used to treat localised disease since the 1940s, and in the 1960s, effective combination chemotherapy regimens were introduced for ...
Lynny Yung, David C. Linch
openaire +4 more sources
Nursing Standard, 2004
Hodgkin's lymphoma is a malignant disease of the lymphatic system. This article gives an overview of the disease process and the classification and staging of Hodgkin's lymphoma. The nursing care and psychological support of these patients during radiotherapy and chemotherapy treatment are also discussed.
Sylvia Cole, Kathleen Dunne
openaire +2 more sources
Hodgkin's lymphoma is a malignant disease of the lymphatic system. This article gives an overview of the disease process and the classification and staging of Hodgkin's lymphoma. The nursing care and psychological support of these patients during radiotherapy and chemotherapy treatment are also discussed.
Sylvia Cole, Kathleen Dunne
openaire +2 more sources
Current Problems in Cancer, 2006
An estimated 8,490 new cases of Hodgkin’s lymphoma were diagnosed in the USA in 2010. Reed–Sternberg cells are the malignant cells in classical Hodgkin’s lymphoma (CD15+, CD30+, and CD45−). In nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL), these cells express B-cell markers (CD20+, CD79a+, and CD45+) and are CD15− and CD30 ...
Michael Crump +2 more
openaire +3 more sources
An estimated 8,490 new cases of Hodgkin’s lymphoma were diagnosed in the USA in 2010. Reed–Sternberg cells are the malignant cells in classical Hodgkin’s lymphoma (CD15+, CD30+, and CD45−). In nodular lymphocyte-predominant Hodgkin’s lymphoma (NLPHL), these cells express B-cell markers (CD20+, CD79a+, and CD45+) and are CD15− and CD30 ...
Michael Crump +2 more
openaire +3 more sources
Hematology/Oncology Clinics of North America, 2009
Hodgkin disease was first described more than 175 years ago. Clinically and histomorphologically, the features of Hodgkin lymphoma are unusual for a lymphoma or for other malignancies. The incidence of Hodgkin lymphoma is estimated to be 7400 new cases per year in the United States, resulting in an age-adjusted yearly rate of 2.7 per 100,000 per year ...
openaire +2 more sources
Hodgkin disease was first described more than 175 years ago. Clinically and histomorphologically, the features of Hodgkin lymphoma are unusual for a lymphoma or for other malignancies. The incidence of Hodgkin lymphoma is estimated to be 7400 new cases per year in the United States, resulting in an age-adjusted yearly rate of 2.7 per 100,000 per year ...
openaire +2 more sources